Chroma Therapeutics Ltd

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong underpinning network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders. The company intends to achieve this goal by: focusing primarily on chromatin biology to build a balanced pipeline, by selecting a broad range of targets with differing mechanistic actions leveraging its links with leading chromatin researchers to provide a renewable pipeline of innovative programmes and a strong intellectual property portfolio focusing its strong medicinal chemistry capabilities on producing only first-in-class or best-in-class drugs, with excellent pharmaceutical properties utilising its novel cell accumulation technology to both enhance its core chromatin programmes, as well as building a highly valuable inflammation portfolio building substantial shareholder value through a balance of in-house development and selected strategic alliances which preserve significant downstream rights

Contact Details: 93 Milton Park Abingdon Oxfordshire OX14 4RY United Kingdom Tel: 44 (0)1235 829120 Fax: 44 (0)1235 829125 Email: pa@chromatherapeutics. Com WWW: www.chromatherapeutics.com/

Recent Publications by Chroma Therapeutics Ltd:
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. CHR-2797 is a novel metalloenzyme inhibitor that is converted into a...	3rd October, 2008	Chroma Therapeutics Ltd., Abingdon, United Kingdom.	Cancer Res. 2008 Aug 15;68(16):6669-79. DOI Direct Link

BioNews Results for Chroma Therapeutics Ltd:
AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera	Pharma Live:  Oct 6 2008 1:40AM Matching: therapeutics
Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference	Pharma Live:  Oct 5 2008 10:43PM Matching: therapeutics
Stem Cell Therapeutics Announces Issuance of Australian Patent	PR-USA.net:  Oct 5 2008 12:03PM Matching: therapeutics
Anika Therapeutics Announces Exclusive Canadian Distribution Agreement for ELEVESS(R) with Canderm Pharma Inc	SmartBrief:  Oct 5 2008 5:39AM Matching: therapeutics
Repros Therapeutics Inc. Announces Closing of Previously Announced Direct Registered Offering	Pharma Live:  Oct 5 2008 9:20PM Matching: therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Chroma Therapeutics Ltd news.

Chroma Therapeutics Ltd Patents:
US Patent No.	Title
7074578	Methods and means of histone methylation
6890709	Assays, methods and means for modulating e2f activity
6747005	Assays, methods and means for modulating nuclear localization

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 243 times since April 2007, the link to the organisation's website has been followed 44 times

Recent Search Terms used to find this page: Chromatherapeutics Milton | Chromatherapeutics Milton | pa@chromatherapeutics.com | chroma therapeutics USA | chroma therapeutics vat number | chroma therapeutics | chroma therapeutics | chroma therapeutics | Chroma Therapeutics | CHROMA THERAPEUTICS LIMITED CEO | .

Search for more companies in Abingdon

Search for more companies in Oxfordshire

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Chroma Therapeutics Ltd